In IgA Nephropathy and FSGS

Proteinuria Could Be Putting Your Patients at High Risk

Proteinuria is a key prognostic indicator and driver of progression in both IgA nephropathy and FSGS1-8

Proteinuria perpetuates a cycle of kidney fibrosis, as proximal tubular reabsorption of excess protein contributes to tubulointerstitial injury4-8

Reduction in proteinuria results in decrease in glomerular pressure and reduction of podocyte damage.1

Lower proteinuria levels are critical to preserving kidney function1,2,9-12


IgA nephropathy
Downward pointing arrows to signify the importance of lowering proteinuria to targeted levels
<1.0 g/d
Downward pointing arrows to signify the importance of lowering proteinuria to targeted levels
<1.5 g/ga
Achieving these targeted proteinuria goals correlates with extended kidney survival

aFSGS partial remission threshold defined as <1.5 g/g with a 40% reduction from baseline.

Evidence-based thresholds translate to clinically meaningful treatment goals

Despite receiving standard-of-care treatment, many patients face a poor prognosis due to elevated proteinuria levels, making the need for novel medications urgent.

FSGS=focal segmental glomerulosclerosis; IgA=immunoglobulin A.


1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int. 2021;100(4S):S1-S276. 2. Troyanov S, et al. J Am Soc Nephrol. 2005;16:1061-1068. 3. Inker LA, et al. Am J Kidney Dis. 2016:1-10. 4. D'Agati VD, et al. New Engl J Med. 2011;365:2398-2411. 5. Remuzzi G, et al. New Engl J Med. 1998;339:1448-1456. 6. Ruggenenti P, et all. Kidney Int. 1998;53:1209-1216. 7. Dhaun N, et al. Br J Pharmacol. 2012;167:720-731. 8. Cravedi P, et al. Br J Clin Pharmacol. 2013;76(4):516-523. 9. Le WB, et al. Nephrol Dial Transplant. 2012;27:1479-1485. 10. Reich HN, et al. J Am Soc Nephrol. 2007;18:3177-3183. 11. Troost JP, et al. Clin J Am Soc Nephrol. 2018;13:414-421. 12. Troost JP, et al. Am J Kidney Dis. 2021;77:216-225. 13. Saleem MA, et al. American Society of Nephrology (ASN) Kidney Week virtual, November 4-7, 2021. PO1529. 14. Raina R, et al. Kidney Dis. 2020;6:22-34. 15. Komers R, et al. Am J Physiol Regul Integr Comp Physiol. 2016:R877-R884. 16. Kohan DE, et al. Kidney Int. 2014;86:896-904.

Sign up for the latest news and updates on IgA nephropathy and FSGS

All fields are required.


    I understand that by checking this box and clicking "Submit," I am submitting my contact information and may receive company and product information communications from Travere Therapeutics™. I also understand that my personal information provided will be processed by Travere Therapeutics™ to provide me access to the latest news and updates. For more information, review our privacy policies.

        Sign up successful

        Thank you for registering

        Back to the top